In addition, the use of brPEI-pcDNA1/MOMPopt improved the potency of the DNA vaccine following aerosol delivery. However, the vaccine formulation and delivery route need to be adapted to obtain a more homogenous vaccine distribution in the upper and lower airways of the birds and to lower the vaccine dose. Delphine S.A. Beeckman Lenvatinib mouse is a post-doctoral fellow of the Research Foundation Flanders (FWO-Vlaanderen) and this institution is acknowledged

for providing a grant. “
“Many infectious pathogens come into contact with the host at mucosal surfaces. Conventional parenteral vaccines are generally ineffective at eliciting mucosal immunity [1], [2] and [3]. Recent efforts have focused on the development of mucosal vaccines in an attempt to combat invading pathogens at the site of contact by efficiently inducing both mucosal and systemic immune responses. However, one major drawback is the intrinsic low immunogenicity of many protein antigens when administered mucosally. Therefore, the need for mucosal adjuvants is pivotal for development of effective and safe mucosal vaccines. The most widely studied mucosal adjuvants are the cholera toxin (CT) from Vibrio cholerae, and its close relative, the heat-labile Selleckchem BLZ945 enterotoxin (LT) from Escherichia coli. Aside from their functioning as enterotoxins, both CT and LT have been shown to function as potent adjuvants via

binding to the ganglioside GM1 receptor, which results in cellular activation, expression of surface molecules and cytokine production [4]. However, intranasal delivery of these bacterial enterotoxins may induce neurotoxic

effects [5] and [6]. Mutant forms of cholera (mCT) and heat-labile toxin (mLT), which lack toxicity while retaining adjuvanticity, have been described [7]. The development of a safe, non-toxic mucosal adjuvant that can be delivered intranasally would be an attractive alternative to bacterial toxins. The first described viral enterotoxin is the rotavirus nonstructural nearly protein 4 (NSP4). NSP4 is capable of inducing dose- and age-dependent diarrhea in neonatal mice without causing histological alterations [8]. A cleavage product, NSP4(112–175), found in the supernatant of rotavirus-infected cell cultures [9] can cause Ca2+ mobilization in vitro and induce dose- and age-dependent diarrhea in vivo, just like the full-length protein. Since bacterial toxins, such as CT and LT, are well established to function as potent mucosal adjuvants, we asked if NSP4 also possesses adjuvant activity. In this study we tested the viral enterotoxin NSP4 from several virus strains for adjuvant activity in mice following intranasal administration of classical model protein antigens and evaluated the mucosal and systemic antibody responses. Six- to eight-week-old inbred BALB/c female mice were obtained from Charles River Laboratories (Wilmington, MA). All animals were housed in microisolator cages throughout the study period as previously described [10] and [11].